Your session is about to expire
← Back to Search
Stem Cell Transplant for Sickle Cell Disease (HaploSCD Trial)
HaploSCD Trial Summary
This trial is studying a high-dose chemotherapy regimen followed by an infusion of stem cells from a partially matched adult family member donor in treating patients with sickle cell disease.
HaploSCD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowHaploSCD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.HaploSCD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had a stroke or brain injury related to my sickle cell disease.I have had at least 3 painful episodes in the last 2 years.I have severe liver scarring.My kidney, liver, heart, and lungs are working well.I can do most activities but may need help.I am not pregnant or breastfeeding.I need regular blood transfusions due to an abnormal TCD test.I may choose to have a liver biopsy to check for excess iron due to frequent blood transfusions.I have a family member who matches my HLA type and is willing to donate.I am mostly bedridden due to my health, not just because of a past stroke.My donor is a family member who does not have sickle cell disease.I have had a stem cell transplant before.I have sickle cell disease or Hemoglobin S Beta thalassemia.I have sickle cell disease with an untreated infection.I have had at least two episodes of severe chest pain.
- Group 1: Haplo Stem Cell Transplantation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In how many different areas is this study offered?
"This study has six active sites, which are New york Medical College in Valhalla, Children's Hospital and Research Center Oakland in Oakland, and Medical College of Wisconsin/Children's Hospital of Wisconsin in Milwaukee. Other locations include _____, _____, and _____."
Does this clinical trial have an age limit? If so, what is the maximum age of participants?
"According to the age requirements specified in this study's inclusion criteria, would-be participants must be between 2 and 20 years old."
Could I possibly qualify to participate in this test?
"Eligible participants for this study must be between 2 and 20 years old, have a diagnosis of sickle cell anemia, and demonstrate one or more of the following Sickle Cell Disease Complications: Recurrent painful events (at least 3 in the 2 years prior to enrollment), minimum of two episodes of acute chest syndrome, Karnofsky or Lansky (age appropriate) Performance Score ≥50%."
Are there any opportunities for people to participate in this research?
"The clinical trial in question is no longer actively recruiting patients. Originally posted on 2012-01-01, the study was last updated on 27 September 2022. There are currently 202 other studies that may be of interest to you."
What is the mortality rate for CD34 selected T-cell depleted allogeneic SCT?
"We have given CD34 selected T-cell depleted allogeneic SCT a score of 2. This is based on it being a phase 2 trial, where while there is some evidence suggesting its safety, there is currently no data affirming its efficacy."
Share this study with friends
Copy Link
Messenger